[{"NetIncomeLossConverted_1_Q2_USD":-27215000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":-48009000.0,"CommonStockSharesOutstanding_0_Q2_shares":59015868.0,"StockholdersEquity_0_Q2_USD":360498000.0,"EarningsPerShareBasic_1_Q2_USD":-0.46,"EarningsPerShareBasic_2_Q2_USD":-1.11,"RevenuesConverted_1_Q2_USD":10025000.0,"RevenuesConverted_2_Q2_USD":21571000.0,"Assets_0_Q2_USD":453957000.0,"CommonStockSharesConverted_0_Q2_shares":59015868.0,"NetIncomeLossConverted_2_Q2_USD":-48953000.0,"Ticker":"RVMD","CIK":"1628171","name":"REVOLUTION MEDICINES, INC.","OfficialName":"Revolution Medicines Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1775342076.0","Country":"United States","Sector":"Consumer Durables","Industry":"Specialty Chemicals","Market":"NASDAQ","SP500":"nan","filed":"20200810"}]